BXP.L
Beximco Pharmaceuticals Limited [BXP.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BXP.L Stock Summary
Top 10 Correlated ETFs
BXP.L
Top 10 Correlated Stocks
BXP.L
In the News
BXP.L Financial details
Company Rating
Buy
Market Cap
185.14M
Income
4.61B
Revenue
39.27B
Book val./share
-
Cash/share
-
Dividend
0.03
Dividend %
0.08%
Employees
5.5K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
5.53
Forward P/E
-
PEG
-1.9
P/S
0.65
P/B
0.58
P/C
-
P/FCF
9.46
Quick Ratio
0.09
Current Ratio
1.57
Debt / Equity
0.24
LT Debt / Equity
0.05
-
-
EPS (TTM)
8.14
EPS next Y
-
EPS next Q
-
EPS this Y
-9.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.74%
Revenue last 5Y
11.47%
Revenue Q/Q
5.02%
EPS Q/Q
-
-
-
-
-
SMA20
5.13%
SMA50
5.13%
SMA100
10.81%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
11%
ROC
0.13%
Gross Margin
44%
Oper. Margin
18%
Profit Margin
12%
Payout
34%
Shs Outstand
1.13B
Shs Float
297.32M
-
-
-
-
Target Price
-
52W Range
33.3-60.0
52W High
-30.83%
52W Low
+25.76%
RSI
61
Rel Volume
64.41
Avg Volume
59.77K
Volume
3.85M
Perf Week
2.47%
Perf Month
7.79%
Perf Quarter
16.9%
Perf Half Y
9.21%
-
-
-
-
Beta
0.65
-
-
Volatility
0.36%, 1.26%
Prev Close
0%
Price
41.5
Change
-
BXP.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 51.15 | 57.44 | 66.11 | 77.71 | 88 | |
| Net income per share | 6.8 | 7.88 | 11.49 | 11.48 | 10.34 | |
| Operating cash flow per share | 6.63 | 12.43 | 0 | 12.31 | 13.64 | |
| Free cash flow per share | -3.55 | 7.33 | -5.73 | 5.72 | 7.56 | |
| Cash per share | 2.09 | 1.42 | 1.51 | 2.62 | 2.55 | |
| Book value per share | 66.32 | 72.87 | 83.01 | 91.01 | 97.89 | |
| Tangible book value per share | 62.73 | 69.46 | 79.44 | 88.32 | 94.62 | |
| Share holders equity per share | 66.32 | 72.87 | 83.01 | 91.01 | 97.89 | |
| Interest debt per share | 32.54 | 25.83 | 19.03 | 29.98 | 26.66 | |
| Market cap | 16.23B | 14.88B | 44.06B | 34.79B | 21.35B | |
| Enterprise value | 29.1B | 24.75B | 51.02B | 45.99B | 30.83B | |
| P/E ratio | 5.35 | 4.23 | 8.59 | 6.79 | 4.63 | |
| Price to sales ratio | 0.71 | 0.58 | 1.49 | 1 | 0.54 | |
| POCF ratio | 5.48 | 2.68 | 0 | 6.33 | 3.51 | |
| PFCF ratio | -10.24 | 4.55 | -17.22 | 13.62 | 6.33 | |
| P/B Ratio | 0.55 | 0.46 | 1.19 | 0.86 | 0.49 | |
| PTB ratio | 0.55 | 0.46 | 1.19 | 0.86 | 0.49 | |
| EV to sales | 1.28 | 0.97 | 1.73 | 1.33 | 0.79 | |
| Enterprise value over EBITDA | 5.85 | 4.37 | 7.05 | 5.98 | 4.19 | |
| EV to operating cash flow | 9.83 | 4.46 | 0 | 8.37 | 5.07 | |
| EV to free cash flow | -18.36 | 7.57 | -19.94 | 18.01 | 9.14 | |
| Earnings yield | 0.19 | 0.24 | 0.12 | 0.15 | 0.22 | |
| Free cash flow yield | -0.1 | 0.22 | -0.06 | 0.07 | 0.16 | |
| Debt to equity | 0.46 | 0.32 | 0.21 | 0.3 | 0.24 | |
| Debt to assets | 0.27 | 0.21 | 0.15 | 0.19 | 0.15 | |
| Net debt to EBITDA | 2.59 | 1.74 | 0.96 | 1.46 | 1.29 | |
| Current ratio | 1.04 | 1.15 | 1.47 | 1.45 | 1.57 | |
| Interest coverage | 4.92 | 5.53 | 7.75 | 6.89 | 5.61 | |
| Income quality | 0 | 0 | 0 | 1.07 | 0 | |
| Dividend Yield | 0.03 | 0.04 | 0.01 | 0.05 | 0.07 | |
| Payout ratio | 0.17 | 0.17 | 0.11 | 0.32 | 0.34 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.08 | 0.08 | |
| Capex to operating cash flow | -1.54 | -0.41 | 0 | -0.54 | -0.45 | |
| Capex to revenue | -0.2 | -0.09 | -0.09 | -0.08 | -0.07 | |
| Capex to depreciation | 0 | 0 | 0 | -7.94 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 100.73 | 113.68 | 146.52 | 153.35 | 150.91 | |
| ROIC | 0.09 | 0.1 | 0.12 | 0.1 | 0.1 | |
| Return on tangible assets | 0.06 | 0.07 | 0.1 | 0.08 | 0.07 | |
| Graham Net | -33.83 | -29.88 | -15.53 | -51.84 | -31.21 | |
| Working capital | 518.33M | 1.69B | 4.42B | 5.68B | 7.61B | |
| Tangible asset value | 27.98B | 30.98B | 35.44B | 39.4B | 42.22B | |
| Net current asset value | -6.09B | -4.27B | -1.11B | -3.09B | -661.26M | |
| Invested capital | 0.46 | 0.32 | 0.21 | 0.3 | 0.24 | |
| Average receivables | 0 | 0 | 2.25B | -3.31B | -5.56B | |
| Average payables | 1.04B | 1.28B | 1.71B | 2.22B | 3B | |
| Average inventory | 6.19B | 6.69B | 7.26B | 9.46B | 12.04B | |
| Days sales outstanding | 0 | 0 | 55.71 | -117.12 | 0 | |
| Days payables outstanding | 32.67 | 38.94 | 46.07 | 47.72 | 58.72 | |
| Days of inventory on hand | 199.02 | 178.88 | 182.96 | 215.34 | 215.36 | |
| Receivables turnover | 0 | 0 | 6.55 | -3.12 | 0 | |
| Payables turnover | 11.17 | 9.37 | 7.92 | 7.65 | 6.22 | |
| Inventory turnover | 1.83 | 2.04 | 1.99 | 1.69 | 1.69 | |
| ROE | 0.1 | 0.11 | 0.14 | 0.13 | 0.11 | |
| Capex per share | -10.19 | -5.1 | -5.73 | -6.59 | -6.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q4
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 19.59 | 21.94 | 22.17 | 21.42 | 0 | |
| Net income per share | 1.89 | 3.24 | 2.77 | 2.13 | 0 | |
| Operating cash flow per share | 2.18 | 3.24 | 2.77 | 2.13 | 0 | |
| Free cash flow per share | -0.29 | 1.71 | 1.22 | 1.01 | 0 | |
| Cash per share | 2.62 | 1.96 | 2.79 | 2.21 | 0 | |
| Book value per share | 91.01 | 94.25 | 93.52 | 95.65 | 0 | |
| Tangible book value per share | 88.32 | 91.73 | 91.03 | 93.05 | 0 | |
| Share holders equity per share | 91.01 | 94.25 | 93.52 | 95.65 | 0 | |
| Interest debt per share | 28.38 | 27.62 | 26.53 | 26.25 | 0 | |
| Market cap | 34.79B | 34.39B | 30.42B | 22.08B | 0 | |
| Enterprise value | 45.99B | 45.53B | 40.67B | 32.48B | 9.48B | |
| P/E ratio | 10.32 | 5.94 | 6.15 | 5.81 | 0 | |
| Price to sales ratio | 3.98 | 3.51 | 3.08 | 2.31 | 0 | |
| POCF ratio | 35.76 | 23.76 | 24.59 | 23.22 | 0 | |
| PFCF ratio | -269.39 | 44.97 | 56 | 49.11 | 0 | |
| P/B Ratio | 0.86 | 0.82 | 0.73 | 0.52 | 0 | |
| PTB ratio | 0.86 | 0.82 | 0.73 | 0.52 | 0 | |
| EV to sales | 5.26 | 4.65 | 4.11 | 3.4 | 0.94 | |
| Enterprise value over EBITDA | 35.52 | 20.76 | 20.45 | 20.99 | 5.83 | |
| EV to operating cash flow | 47.27 | 31.46 | 32.88 | 34.17 | 5.34 | |
| EV to free cash flow | -356.14 | 59.54 | 74.88 | 72.27 | 10.07 | |
| Earnings yield | 0.02 | 0.04 | 0.04 | 0.04 | 0 | |
| Free cash flow yield | 0 | 0.02 | 0.02 | 0.02 | 0 | |
| Debt to equity | 0.3 | 0.29 | 0.28 | 0.27 | 0.24 | |
| Debt to assets | 0.19 | 0.18 | 0.17 | 0.17 | 0.15 | |
| Net debt to EBITDA | 8.65 | 5.08 | 5.16 | 6.72 | 5.83 | |
| Current ratio | 1.45 | 1.59 | 1.47 | 1.58 | 1.57 | |
| Interest coverage | 4.05 | 6.79 | 5.92 | 4.77 | 5 | |
| Income quality | 1.15 | 1 | 1 | 1 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0.07 | 0 | |
| Payout ratio | 0.01 | 0 | 0 | 1.63 | 0.01 | |
| Sales general and administrative to revenue | 0.11 | 0.03 | 0.03 | 0.04 | 0.02 | |
| Research and developement to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.08 | 0.08 | 0.07 | 0.07 | 0.08 | |
| Capex to operating cash flow | -1.13 | -0.47 | -0.56 | -0.53 | -0.47 | |
| Capex to revenue | -0.13 | -0.07 | -0.07 | -0.05 | -0.08 | |
| Capex to depreciation | -8.46 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 62.19 | 82.94 | 76.39 | 67.72 | 0 | |
| ROIC | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Return on tangible assets | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Graham Net | -28.15 | -26.64 | -29.47 | -32.64 | 0 | |
| Working capital | 5.68B | 7.32B | 6.85B | 7.62B | 7.61B | |
| Tangible asset value | 39.4B | 40.92B | 40.61B | 41.51B | 42.22B | |
| Net current asset value | -3.09B | -1.8B | -2.32B | -1.36B | -661.26M | |
| Invested capital | 0.3 | 0.29 | 0.28 | 0.27 | 0.24 | |
| Average receivables | 3.55B | 3.11B | 3.27B | 1.65B | 0 | |
| Average payables | 2.69B | 2.5B | 2.91B | 3.38B | 3.5B | |
| Average inventory | 10.87B | 11.8B | 12.96B | 13.39B | 13.15B | |
| Days sales outstanding | 30.51 | 29.86 | 30.02 | 0 | 0 | |
| Days payables outstanding | 43.11 | 42.64 | 54.2 | 58.46 | 54.8 | |
| Days of inventory on hand | 194.56 | 209.31 | 221.95 | 224.91 | 201 | |
| Receivables turnover | 2.95 | 3.01 | 3 | 0 | 0 | |
| Payables turnover | 2.09 | 2.11 | 1.66 | 1.54 | 1.64 | |
| Inventory turnover | 0.46 | 0.43 | 0.41 | 0.4 | 0.45 | |
| ROE | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Capex per share | -2.47 | -1.53 | -1.56 | -1.12 | 0 |
BXP.L Frequently Asked Questions
What is Beximco Pharmaceuticals Limited stock symbol ?
Beximco Pharmaceuticals Limited is a BD stock and trading under the symbol BXP.L
What is Beximco Pharmaceuticals Limited stock quote today ?
Beximco Pharmaceuticals Limited stock price is $41.5 today.
Is Beximco Pharmaceuticals Limited stock public?
Yes, Beximco Pharmaceuticals Limited is a publicly traded company.
Company Profile
- Volume Average 59.77K
- Market Capitalization 185.14M
- Employee 5.5K
- CEO Mr. Md. Nazmul Hassan MP
- Headquarters Dhaka,BD
- IPO Date 2005-10-21
-
Website
https://www.beximcopharma.com 
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
